Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01010217 · ClinicalTrials.gov registry record · Phase 2
Mismatched Transplantation Using High-dose Post-transplant Cyclophosphamide
A Phase 2 study, sponsored by M.D. Anderson Cancer Center.
- Completed
- Registry status
- Phase 2
- Development phase
- 176
- Enrollment target
NCT01010217: Completed Phase 2 study, sponsored by M.D. Anderson Cancer Center.
NCT01010217 is a Phase 2 study that has completed, run by M.D. Anderson Cancer Center. The registered enrollment target is 176 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01010217, a Phase 2 study, has completed, sponsored by M.D. Anderson Cancer Center.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 176 participants
- Enrollment target
Study Summary
The goal of this clinical research study is to learn about the safety of giving a stem cell transplant from a tissue-mismatched donor, followed by cyclophosphamide, to patients with certain types of blood disorders or blood cancers. Melphalan, thiotepa, and fludarabine will also be given before the transplant. Researchers will study the health status of these patients at 3 months after the transplant.
Interventions
- DRUG Cyclophosphamide
- DRUG Fludarabine
- DRUG Melphalan
- DRUG Mesna
- DRUG Rituximab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 176 participants |
| Start Date | 2009-11-05 |
| Est. Completion | 2017-10-05 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01010217
The ClinicalTrials.gov registry entry for NCT01010217 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 176 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is M.D. Anderson Cancer Center, which has 2,692 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Cyclophosphamide is the first listed.
NCT01010217 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01010217 about?
NCT01010217 is a clinical study titled "Mismatched Transplantation Using High-dose Post-transplant Cyclophosphamide". The goal of this clinical research study is to learn about the safety of giving a stem cell transplant from a tissue-mismatched donor, followed by cyclophosphamide, to patients with certain types of blood disorders or blood cancers. Melphalan, thiotepa, and fludarabine will also be given before the ...
What is the current status of trial NCT01010217?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 176 participants. The study started on 2009-11-05. Estimated completion is 2017-10-05.
What interventions are being tested in trial NCT01010217?
The interventions under investigation include: Cyclophosphamide (DRUG), Fludarabine (DRUG), Melphalan (DRUG), Mesna (DRUG), Rituximab (DRUG).
Who is sponsoring clinical trial NCT01010217?
This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.